Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) insider Benjamin T. Dake sold 11,068 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $27.97, for a total value of $309,571.96. Following the sale, the insider now owns 1,291 shares in the company, valued at approximately $36,109.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Aerovate Therapeutics Price Performance
NASDAQ:AVTE opened at $29.57 on Friday. Aerovate Therapeutics, Inc. has a 1-year low of $9.41 and a 1-year high of $29.99. The business's 50-day moving average price is $22.19 and its two-hundred day moving average price is $17.71.
Wall Street Analyst Weigh In
Several analysts have recently commented on the company. Jefferies Financial Group started coverage on Aerovate Therapeutics in a report on Monday. They set a "buy" rating and a $65.00 target price on the stock. Wells Fargo & Company started coverage on Aerovate Therapeutics in a research note on Friday, December 8th. They set an "equal weight" rating and a $35.00 price target on the stock.
Check Out Our Latest Stock Analysis on Aerovate Therapeutics
Hedge Funds Weigh In On Aerovate Therapeutics
These AI trades triggered this morning (545% return)
From Prosper Trading Academy | Ad
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Click Here To Get Your Free Copy
Several hedge funds have recently added to or reduced their stakes in the stock. TCG Crossover Management LLC raised its position in shares of Aerovate Therapeutics by 103.6% during the second quarter. TCG Crossover Management LLC now owns 2,201,274 shares of the company's stock worth $37,752,000 after purchasing an additional 1,120,000 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of Aerovate Therapeutics during the second quarter worth about $20,479,000. Great Point Partners LLC raised its position in shares of Aerovate Therapeutics by 23.4% during the second quarter. Great Point Partners LLC now owns 932,158 shares of the company's stock worth $15,987,000 after purchasing an additional 176,538 shares during the period. BlackRock Inc. raised its position in shares of Aerovate Therapeutics by 2.3% during the first quarter. BlackRock Inc. now owns 746,934 shares of the company's stock worth $13,691,000 after purchasing an additional 17,126 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Aerovate Therapeutics by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 626,831 shares of the company's stock worth $14,185,000 after purchasing an additional 27,729 shares during the period.
About Aerovate Therapeutics
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
